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Abstract
Background: The current World Health Organization classification recognises 12 major subtypes of renal cell carcinoma
(RCC). Although these subtypes differ on molecular and clinical levels, they are generally managed as the same disease,
simply because they occur in the same organ. Specifically, there is a paucity of tools to risk-stratify patients with papillary
RCC (PRCC). The purpose of this study was to develop and evaluate a tool to risk-stratify patients with clinically non-
metastatic PRCC following curative surgery.
Methods: We studied clinicopathological variables and outcomes of 556 patients, who underwent full resection of
sporadic, unilateral, non-metastatic (T1–4, N0–1, M0) PRCC at five institutions. Based on multivariable Fine-Gray
competing risks regression models, we developed a prognostic scoring system to predict disease recurrence. This was
further evaluated in the 150 PRCC patients recruited to the ASSURE trial. We compared the discrimination, calibration
and decision-curve clinical net benefit against the Tumour, Node, Metastasis (TNM) stage group, University of California
Integrated Staging System (UISS) and the 2018 Leibovich prognostic groups.
Results: We developed the VENUSS score from significant variables on multivariable analysis, which were the presence
of VEnous tumour thrombus, NUclear grade, Size, T and N Stage. We created three risk groups based on the VENUSS
score, with a 5-year cumulative incidence of recurrence equalling 2.9% in low-risk, 15.4% in intermediate-risk and 54.5%
in high-risk patients. 91.7% of low-risk patients had oligometastatic recurrent disease, compared to 16.7% of intermediate-
risk and 40.0% of high-risk patients. Discrimination, calibration and clinical net benefit from VENUSS appeared to be
superior to UISS, TNM and Leibovich prognostic groups.
Conclusions: We developed and tested a prognostic model for patients with clinically non-metastatic PRCC, which is
based on routine pathological variables. This model may be superior to standard models and could be used for tailoring
postoperative surveillance and defining inclusion for prospective adjuvant clinical trials.
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Background
The 2016 World Health Organization classification rec-
ognises 12 major subtypes of renal cell carcinoma (RCC)
with distinct morphologic, molecular and clinical fea-
tures [1]. Papillary RCC (PRCC) is the second most
common subtype and accounts for 15% of all cases [2].
PRCC is often subdivided into type 1 and 2, but studies
did not confirm the independent prognostic value of
PRCC type in localised disease [3, 4]. Compared with
conventional clear cell RCC, PRCC is thought to have a
more favourable prognosis in the non-metastatic stage
[5], while patients with metastatic disease have worse
outcomes than their counterparts [6]. However, although
RCC subtypes differ on molecular and clinical levels,
they are generally managed as the same disease, simply
because they occur in the same organ and due to the
fact that there is little data on the efficacy of available
treatment options.
Prognostic factors are crucial for counselling, planning
follow-up and selecting candidates for adjuvant trials. In
general, the protocol of follow-up imaging studies re-
flects the risk, the site and the timing of recurrence, with
more frequent imaging obtained in high-risk patients
within the first years after surgery [7]. Further, it appears
likely that patients at a higher risk for tumour recur-
rence are most in need of effective adjuvant therapies
and should therefore be included in adjuvant trials [8].
In this regard, TNM stage has traditionally been used to
establish the risk of tumour recurrence for all RCC sub-
types, but has limited accuracy when used alone [9].
TNM has been supplemented by several additional inde-
pendent prognostic factors such as grade and coagulative
tumour necrosis [10, 11]; however, these prognostic
models were often established for clear cell RCC only
[12, 13] or all RCC subtypes [14, 15], disregarding the
considerable proportion of patients with PRCC. Further,
the prognostic models or modifications thereof were
used to define inclusion criteria and to risk-stratify PRCC
patients for adjuvant trials such as SORCE (NCT00492258)
or ASSURE (NCT00326898, E2805) without previous valid-
ation, and others such as the 2018 Leibovich prognostic
system [11] were single centre, not externally validated and
not assessed for calibration or clinical net benefit. Thus,
there is a great need for refinement of prognostic models in
patients with PRCC, just as there is a need to establish a
more specific approach to managing this second common-
est subtype of RCC [16]. Here, we develop and evaluate a
prognostic model for non-metastatic PRCC following cura-
tive surgery.
Methods
Development cohort
The development cohort included 556 bi-nephric patients,
who underwent curative surgery for sporadic, non-
metastatic (M0), unilateral PRCC at five international
RCC centres between 2000 and 2016. Participating institu-
tions obtained the required local institutional review
board approval for retrospective analyses and provided
required data-sharing agreements prior to initiation of the
study.
Pre-operative clinical staging was performed through
physical examination and computed tomography (CT)
scans of the chest, abdomen and pelvis. None of the pa-
tients had preoperative systemic therapy, local radiother-
apy or embolization, and all had complete macroscopic
resection of disease. Two hundred eighty-three patients
underwent radical nephrectomy, while 273 had a partial
nephrectomy. A concomitant lymph node dissection was
performed in 86 cases, with a median of five lymph nodes
removed (range 1–32). Those who did not undergo a
lymph node dissection (pNx) were clinically N0.
Pathological specimens were reviewed by specialised
genitourinary pathologists at each institution. Tumours
were staged clinically and pathologically according to
the 2010 American Joint Committee on Cancer Tumour,
Node, Metastasis (TNM) classification, and re-classified
if older systems were used initially. Further recorded
clinicopathological variables included nuclear grade [17],
pathological tumour size, presence and extent of venous
tumour thrombus, papillary type 1 or 2, sarcomatoid fea-
tures and coagulative tumour necrosis. The presence of
coagulative tumour necrosis was analysed microscopic-
ally and defined as homogeneous clusters and sheets of
degenerating and dead cells. Clinicopathological vari-
ables were then used to assign prognostic groups ac-
cording to UISS [18] and the 2018 Leibovich prognostic
groups [11].
Postoperative follow-up was institution- and physician-
dependent, but generally followed national and inter-
national guidelines at that time. In general, patients were
seen at least every 3 to 6months in year 1, every 6months
in year 2 and annually thereafter. Follow-up visits con-
sisted of a physical examination, laboratory tests and CT
scans of chest, abdomen and pelvis. Sixty PRCC recur-
rences were detected during a median follow-up of 50
months. Local recurrence, solitary metastasis and oligo-
metastases defined as < 3 lesions at a single site were con-
sidered oligometastatic recurrent disease, which may be
potentially curable by local therapies [19, 20]. There were
116 deaths, including 44 from PRCC.
Independent cohort
ASSURE (Adjuvant Sunitinib or Sorafenib for Un-
favourable REnal-cell carcinoma, ECOG-ACRIN E2805,
NCT00326898) was a double-blind, placebo-controlled,
randomised, phase 3 trial, which enrolled 1943 patients
with completely resected non-metastatic RCC at high risk
for recurrence. After a median follow-up of 5.8 years, there
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were no differences in disease-free survival for adjuvant
sunitinib or sorafenib relative to placebo. The trial in-
cluded patients with all RCC subtypes, including 150 with
intermediate high-risk and very-high-risk PRCC according
to modified UISS criteria [18]. There was central path-
ology review and standardised postoperative imaging, as
outlined in the trial protocol [21]. We used the data of
these patients for evaluation of our model. Of the 150 pa-
tients, 57 recurred and 33 died, including 31 with recur-
rent disease. Access to individual patient data was granted
through Project Data Sphere (https://www.projectdata
sphere.org/, ID 435).
Statistical analysis
The primary outcome measure of this study was disease
recurrence, which was calculated from the date of surgery
to the date of first recurrence. The date of censoring for
those alive was the date of last follow-up imaging. We de-
fined recurrence according to the DATECAN renal cancer
group, i.e. as local, regional recurrence or metastases or
contralateral RCC, whichever occurred first [22]. Median
follow-up was calculated using the inverse Kaplan-Meier
approach.
We used Fine and Gray’s competing-risk regression to
model the data, as this accounts for the competing risk
of death without previous recurrence. Potential predictors
of recurrence were analysed by univariable and multivari-
able models. Owing to the possibility of a nonlinear rela-
tionship between tumour size and recurrence, tumour size
was also analysed using restricted cubic splines. We per-
formed subsequent categorisation as a non-linear relation-
ship was observed. After the univariable regression analysis,
we fitted multivariable models. The initial multivariable
model included all significant variables of the univariable
analysis. Subsequently, the model was reduced through
backward variable selection with the likelihood ratio criter-
ion (inclusion/exclusion criteria: p ≤ 0.05/p > 0.1). A simple
scoring algorithm was developed based on the final multi-
variable model, as described previously [23]. The coefficient
for each variable was divided by the highest coefficient (i.e.
lymph node metastasis), multiplied by 3 and rounded to
the nearest integer.
We obtained various measures to analyse model per-
formance. The overall performance was measured by the
concordance index (c index), adapted for competing
risks [24]. The internal validity of the score was evalu-
ated by 500 bootstrap re-samples. We used calibration
plots to compare predicted probabilities at 5 years to the
observed frequencies (pec library in R by TA Gerts) [25].
A decision curve analysis (DCA) was applied to determine
whether the clinical value of the newly derived model in-
creased the net benefit over a realistic range of threshold
probabilities [26]. C indices, calibration and DCA of the
derived score and risk groups were compared with other
risk group definitions, including the UISS, TNM and
Leibovich groups.
In the ASSURE cohort, the score was calculated from
the data obtained; however, tumour size and presence of
venous tumour thrombus were not provided from Pro-
ject Data Sphere. We obtained these variables indirectly
in a subgroup of patients through trial inclusion criteria
and logical vectors (i.e. T2 is greater than 4 cm, T1 and
T2 have no tumour thrombus in renal vein or IVC). For
the remaining missing variables, we used the Multivari-
ate Imputation by Chained Equations algorithm to gen-
erate five imputations [27] using the mice library in R.
mice creates multiple imputations (replacement values)
for multivariable missing data using Gibbs sampling.
The method is based on Fully Conditional Specification,
where each incomplete variable is imputed by a separate
model. We followed published guidelines for obtaining
final estimates after multiple imputations [28], including
Rubin’s rules to pool model parameters from the five
imputed datasets [29].
We used STATA (Stata Inc., College Station, USA) for
DCA and R (The R Foundation for Statistical Computing,
Vienna, Austria; libraries survival, rms, riskRegression,
mice, pec) for statistical analyses. Statistical testing was
two-sided, and a p value < 0.05 was considered statistically
significant.
Results
Characteristics
Table 1 details characteristics of the 556 patients. Within
a median postoperative follow-up interval of 53 months
(SE = 3months), disease recurrence was detected in 60
patients at a median of 12.5 months (IQR = 7–26.5). The
cumulative incidence of recurrence was 5.9% (95% CI =
4.9–6.9%) at 1 year, 9.0% (95% CI = 7.7–10.2%) at 2 years
and 11.7% (95% CI = 10.2–13.2%) at 5 years. The first re-
currence was located in the chest in 30 (50.0%) and the
abdomen in 49 patients (81.7%), with 20 patients (33.3%)
developing their first recurrence in both the chest and
abdomen. One patient recurred in a cervical node but
had no concomitant metastases in chest and abdomen at
that time. Figure 1 demonstrates the risk of recurrence
for all patients and according to site. The first recur-
rence was oligometastatic in 26 (43.3%).
Prognostic factors and prognostic model
On univariable analysis, increasing tumour size (p <
0.001), T stage (p < 0.001), N stage (p < 0.001), nuclear
grade (p < 0.001), presence of venous tumour thrombus
(p < 0.001), tumour necrosis (p < 0.001), fat invasion (p <
0.001), papillary type (p < 0.001) and sarcomatoid fea-
tures (p = 0.019) were all associated with an increased
risk for recurrence (Table 2). With regard to tumour
size, each 1-cm increase was associated with an 18%
Klatte et al. BMC Medicine          (2019) 17:182 Page 3 of 10
increase in the risk of recurrence (HR = 1.18, 95% CI =
1.12–1.23). The relationship between tumour size and
recurrence was further analysed using restricted cubic
splines. In this analysis, the risk for recurrence increased
after 4 cm and subsequently reached a plateau at 10 cm
(Additional file 3: Figure S3). Tumour size was therefore
categorised at 4 and 10 cm. On the multivariable ana-
lysis, tumour size, T stage, N stage, grade and presence
of venous tumour thrombus retained in the final model
(Table 2).
The coefficients of this model were used to develop
the continuous VENUSS (VEnous extension, NUclear
grade, Size, Stage) score (Table 3, Fig. 1b), which ranges
from 0 (lowest possible score) to 11 (highest possible
score). Based on the VENUSS score, we defined three
groups with regard to the risk of recurrence: low risk
(0–2 points), intermediate risk (3 to 5 points) and high
risk (6 points or greater) (Table 3, Fig. 1c). The low-risk
group comprised 63.5% (n = 353), the intermediate-risk
group 24.3% (n = 135) and the high-risk group 12.2%
(n = 68) of patients. The 5-year cumulative incidence of
recurrence ranged from 2.9% (95% CI = 1.9-3.9%) in the
low-risk group to 54.5% (95%CI = 47.3–61.8%) in the
high-risk group (Fig. 1c). Recurrences were oligometa-
static in 91.7% (11/12) of recurring low-risk patients,
16.7% (3/18) of recurring intermediate-risk patients and
40.0% (12/30) of recurring high-risk patients (p < 0.001).
In the 11 recurring low-risk patients, disease recurred in
the abdomen in 9 (8 oligometastatic) and in the chest in
3 (all oligometastatic). In contrast, a preponderance of
recurrent site was not observed in the intermediate- and
high-risk groups.
Using bootstrapping for internal validation, the c index
at 1 year, 2 years and 5 years was 91.4%, 87.2%, and
83.9% for the continuous VENUSS score, and 89.8%,
84.2% and 81.1% for the VENUSS group, respectively
(Table 4). The predicted probability was comparable to
the observed frequency of recurrence, indicating good
calibration (Fig. 2a, Additional file 4: Figure S4). The
corresponding competing-risks models are reported in
Additional file 2: Table S2. Both the VENUSS score and
the VENUSS group showed greater c indices at every
time point than UISS, TNM and Leibovich groups
(Table 4). The DCA demonstrated a moderate net bene-
fit of the VENUSS score and group compared with the
standard models in threshold probabilities between 10
and 40% (Fig. 2b).
Performance in an independent cohort
Characteristics of the 150 PRCC patients enrolled in
ASSURE are presented in Additional file 1: Table S1.
Within a median follow-up of 61 months (SE = 2
months), 57 patients experienced disease recurrence.
The estimated cumulative incidence of recurrence was
19.0% at 1 year, 30.9% at 2 years and 38.1% at 5 year,
without a statistically significant difference across the
three trial arms (p = 0.83).
The median VENUSS score was 5 (IQR 4–8, range 2–
11), and 4% were grouped as VENUSS low risk, 50% as
Table 1 Clinicopathological variables of 556 patients with
unilateral PRCC treated with partial or radical nephrectomy
(development cohort)
Variable Category
Age, years Median 63
IQR 54–70
Gender, n (%) Female 145 (26.1)
Male 411 (73.9)
T stage, n (%) pT1 370 (66.5)
pT2 61 (11.0)
pT3 123 (22.1)
pT4 2 (0.4)
N stage, n (%) pNx/pN0 537 (96.6)
pN1 19 (3.4)
Nuclear grade, n (%) 1 or 2 381 (68.5)
3 or 4 175 (31.5)
Tumour size, n (%) 4.0 cm or less 285 (51.3)
4.1 to 10.0 cm 219 (39.4)
10.1 cm or greater 52 (9.4)
Median 4.0
IQR 2.7–6.3
Surgical margin, n (%) Negative 525 (94.4)
Positive 31 (5.6)
Venous tumour thrombus, n (%) None 524 (94.2)
Renal vein 15 (2.7)
Cava 17 (3.1)
Perinephric/sinus fat invasion,
no venous tumour thrombus, n (%)
– 93 (16.7)
Papillary type, n (%) Type 1 227 (46.0)
Type 2 266 (54.0)
Tumour necrosis, n (%) – 254 (45.7)
Sarcomatoid features, n (%) – 11 (2.0)
UISS, n (%) Low/intermediate risk 335 (60.3)
Intermediate high risk 141 (25.4)
Very high risk 80 (14.4)
2018 Leibovich group, n (%) Low (group 1) 322 (57.9)
Intermediate (group 2) 102 (18.3)
High (group 3) 132 (23.7)
TNM group, n (%) I 369 (66.4)
II 60 (10.8)
III 125 (22.5)
IV 2 (0.4)
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intermediate risk and 46% as high risk. Coefficients, SHR
and 95% CI of competing risk models are shown in Add-
itional file 2: Table S2. Both the VENUSS score and
group showed better discrimination than UISS, TNM
and Leibovich groups at every investigated time point
(Table 4). All models were moderately well calibrated
(Additional file 5: Figure S5A). The DCA showed a net
benefit of these models in threshold probabilities of
more than 20% (Additional file 5: Figure S5B). Add-
itional file 6: Figure S6 shows cumulative incidence
curves according to UISS, Leibovich group and VENUSS
group.
Discussion
In this study, we developed the VENUSS prognostic
score for clinically non-metastatic PRCC, which is based
Fig. 1 Cumulative incidence of disease recurrence of 556 who underwent surgery for non-metastatic papillary renal cell carcinoma and according
to the first site of recurrence. Twenty patients first recurred simultaneously in the abdomen and chest and are included in both curves. a Overall,
the cumulative incidence rate of disease recurrence was 11.7% at 5 years. The most frequent site of recurrence was the abdomen. b Cumulative
incidence curve of disease recurrence according to VENUSS score. c Cumulative incidence curve of disease recurrence according to VENUSS group
Table 2 Univariable and multivariable Fine-Gray competing risks models predicting PRCC recurrence, while accounting for the
competing risk of death without previous recurrence
Univariable Multivariable
Variable Category Coeff SE SHR 95% CI p Coeff SE SHR 95% CI p
Tumour size 0.1–4.0 cm Reference Reference
4.1–10.0 cm 1.64 0.34 5.15 2.60–10.2 < 0.001 1.00 0.38 2.73 1.31–5.68 0.007
> 10 cm 2.52 0.40 12.38 5.63–27.2 < 0.001 1.09 0.49 2.97 1.14–7.74 0.026
T stage pT1 Reference Reference
pT2 1.47 0.41 4.36 1.94–9.8 < 0.001 0.69 0.44 1.99 0.84–4.69 0.12
pT3 2.09 0.30 7.99 4.48–14.3 < 0.001 0.91 0.36 2.48 1.21–5.05 0.013
pT4 4.22 0.28 68.3 39.4–118.4 < 0.001 1.15 0.63 3.15 0.92–10.8 0.068
N stage pNx/pN0 Reference Reference
pN1 2.55 0.36 12.8 6.37–25.9 < 0.001 1.49 0.46 4.42 1.78–11.0 0.001
Nuclear grade G1 or G2 Reference Reference
G3 or G4 1.55 0.26 4.73 2.85–7.87 < 0.001 0.93 0.30 2.53 1.42–4.53 0.002
Venous tumour thrombus Absent Reference Reference
Renal vein 2.15 0.48 8.56 3.32–22.1 < 0.001 1.07 0.49 2.93 1.12–7.67 0.029
IVC 2.44 0.35 11.5 5.77–23.0 < 0.001 0.95 0.45 2.57 1.08–6.16 0.034
Papillary type Type 1 Reference
Type 2 1.07 0.31 2.91 1.58–5.34 < 0.001
Fat invasion Present 0.93 0.28 2.53 1.47–4.33 < 0.001
Tumour necrosis Present 1.01 0.27 2.74 1.61–4.67 < 0.001
Sarcomatoid features Present 1.33 0.57 3.77 1.24–11.5 0.019
Surgical margin Positive 0.45 0.46 1.56 0.63–3.86 0.34
Data on papillary type 1 or 2 were available in 493 patients. On multivariable analysis, papillary type, tumour necrosis, fat invasion and sarcomatoid features were
removed from the model during the backward selection process
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on tumour size, T stage, N stage, presence of venous
tumour thrombus and nuclear grade. The performance
was further evaluated in an independent cohort of 150
high-risk PRCC patients from the prospective adjuvant
ASSURE clinical trial. We show that the VENUSS score
and the corresponding VENUSS groups may be superior
to UISS, TNM and the 2018 Leibovich prognostic
groups [11]. VENUSS may be used for patient counsel-
ling, follow-up planning and for prognostic stratification
in adjuvant trials.
There has been no general consensus on how to best
risk-stratify patients with PRCC following curative sur-
gery. Guidelines advocate the use stratification systems
such as UISS [30], which was developed on patients with
all RCC subtypes; however, the majority of tumours
were clear cell [14]. Although both PRCC and clear cell
RCC share prognostic factors such as T stage and N
stage, the individual contribution of each factor to the
overall recurrence risk is different, and some factors
such as tumour necrosis may not be prognostic in PRCC
[11]. Some researchers used the TNM group [19], which
does not appreciate additional prognostic factors such as
venous tumour thrombus and only considers tumour
size indirectly through T stage. Interestingly, prospective
adjuvant trials such as ASSURE and SORCE used a
modified UISS [21] or the 2003 Leibovich score [12] for
defining inclusion and assessing baseline risk, both of
which however were not validated in these patients.
Several PRCC prognostic models were published over
the past years. A nomogram predicting disease-specific
survival was developed and validated in 2010, but included
both patients with and without distant metastases [10]
and may therefore be of limited clinical utility. Buti et al.
[31] developed the GRade, Age, Nodes and Tumour
(GRANT) score from the ASSURE trial cohort for both
clear cell and non-clear cell RCC. Recently, Leibovich et
al. [11] published a prognostic model for PRCC, which is
based on 607 surgically treated patients from the Mayo
Clinic. Based on nuclear grade, fat invasion and the pres-
ence of venous tumour thrombus, the authors proposed
three groups for recurrence and death from PRCC. The c
index of this model was 77%, but calibration (i.e. compar-
ing the predicted probability and the observed frequency)
or clinical net benefits were not assessed [11]. In the
present study, we compared VENUSS with other prognos-
tic models, including UISS, TNM and the 2018 Leibovich
prognostic groups. While the c index of the Leibovich
prognostic groups was comparable with the original publi-
cation [11], VENUSS showed better discrimination in
both the development and the ASSURE cohort. Of note,
UISS was found to be superior to TNM and Leibovich
prognostic groups. However, it is possible that both the
Table 3 The VENUSS (VEnous extension, NUclear grade, Size,
Stage) score and risk groups
Variable Category Score
Tumour size 4.0 cm or less 0
4.1 cm or greater 2
T stage pT1 0
pT2 1
pT3 or T4 2
N stage pNx/pN0 0
pN1 3
Nuclear grade G1 or G2 0
G3 or G4 2
Venous tumour thrombus Absent 0
Present 2
Risk group Low risk 0–2
Intermediate risk 3–5
High risk 6 or greater
Points are assigned from each category, and the sum is used to determine the
final score. Regression coefficient derived scores were similar for size
categories 4.1 to 10 cm and 10.1 cm or greater, T3 and T4 and venous tumour
thrombus present in the renal vein only or IVC, and therefore amalgamated
into single categories. The minimum score is 0, the maximum score is 11
Table 4 Comparison of c indices and bootstrap confidence intervals of VENUSS score, VENUSS group, UISS, TNM and Leibovich
group in predicting recurrence at 1, 2 and 5 years
Cohort Model 1 year 2 years 5 years
Development VENUSS score 91.4 (85.5–95.0) 87.2 (83.8–90.7) 83.9 (78.7–88.6)
VENUSS group 89.8 (84.4–93.5) 84.2 (79.5–88.7) 81.1 (75.5–86.5)
UISS 88.6 (83.7–92.7) 82.9 (78.2–87.7) 79.3 (73.8–84.5)
TNM 83.7 (78.4–88.4) 78.2 (72.8–82.6) 75.9 (70.8–80.4)
2018 Leibovich group 78.7 (72.7–85.4) 78.2 (72.0–82.3) 76.5 (70.9–81.0)
ASSURE VENUSS score 73.2 (64.5–80.4) 68.3 (61.3–76.1) 66.5 (60.5–73.7)
VENUSS group 66.9 (58.7–74.0) 64.9 (59.6–70.8) 64.6 (57.8–69.8)
UISS 64.2 (55.3–71.5) 63.7 (58.0–69.2) 62.5 (56.8–67.3)
TNM 62.0 (54.0–69.3) 59.7 (53.8–66.6) 60.2 (53.9–65.8)
2018 Leibovich group 61.3 (51.6–67.9) 60.0 (52.3–63.8) 58.2 (50.2–62.7)
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UISS and the Leibovich prognostic groups showed a
poorer performance than VENUSS as they were developed
for different endpoints. Indeed, prognostic models are
often used for different endpoints in clinical practice. For
example, the ASSURE trial used the UISS (outcome of
interest: overall survival), but the primary endpoint of
ASSURE was disease-free survival.
Critically, our study included an independent cohort,
which were the PRCC patients of the prospective adjuvant
ASSURE clinical trial. The dataset was available from Pro-
ject Data Sphere, which provides researchers the oppor-
tunity to conduct secondary analyses of prospectively
collected trial data. In this analysis, discrimination and
calibration were worse than in the development cohort,
Fig. 2 a Calibration of the VENUSS score and VENUSS group in predicting recurrence. The grey line represents the performance of an ideal
prognostic model, while the purple and blue solid lines represent the performance of the VENUSS score and group, respectively. The graphs
indicate good calibration. b Smoothed decision curves of VENUSS and other risk definitions predicting PRCC recurrence. Assuming that patients
with PRCC would be treated differently (i.e. would be included in adjuvant trials), the net benefit of VENUSS is plotted against threshold
probabilities and compared to UISS, TNM and Leibovich groups as well as the strategy of putting all or none into an adjuvant trial. Compared
with UISS, TNM and the 2018 Leibovich prognostic group, VENUSS showed an improved net benefit between 10 and 40% threshold probability
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which is due to cohort composition. Indeed, two thirds of
patients in the development cohort had stage I disease,
compared to 10% of patients in ASSURE. While the devel-
opment cohort included consecutive patients, ASSURE
recruited from pre-screened patients with a higher risk of
recurrence. Thus, although both cohorts included the
same subtype of RCC, they were different in terms of the
risk of recurrence due to the different distribution of prog-
nostic factors. Subsequently, differences between study
cohorts led to substantial differences in c indices and cali-
bration, which in turn depend critically on variation of
predictors [32]. As ASSURE included only patients at high
risk of recurrence, there was little variation in predictors
and thus lower discrimination and worse calibration, spe-
cifically in those with a lower risk of recurrence according
to VENUSS. Thus, quality measures in the development
and independent cohort cannot be compared directly, but
VENUSS appeared to be superior to the other prognostic
models.
An interesting observation was that the proportion of
patients with oligometastatic recurrence was greater in
high-risk than intermediate-risk patients. This finding
has to be treated with reservation as the number of
patients becomes low in each subgroup. While further
validation is required, our data emphasise that patients
with high-risk disease may benefit from close follow-up,
as a considerable proportion of patients with oligorecur-
rent disease may be amenable to potentially curative
salvage procedures.
An important benefit of VENUSS is that it is based on
routine pathology and does not include clinical variables
such as performances status or symptoms, which may be
more subjective. There is little extra work for the report-
ing pathologist to assign the score and group. This can
then be used for patient counselling and planning of fol-
low-up.
We analysed one of the largest cohorts of non-meta-
static PRCC, followed established research guidelines for
prognostic modelling [33] and used an independent co-
hort to test the performance of VENUSS and to compare
it do other risk group definitions. However, this study has
a number of limitations, arising mainly from the retro-
spective character of the development cohort, missing
candidate prognostic variables, as well as the possibility of
not having picked up all recurrences. Firstly, the follow-up
regimen was not standardised across centres, but generally
followed international guidelines of the time. As the me-
dian follow-up was 53months, it was not possible to
present evidence beyond the 5-year landmark. Secondly,
as the development cohort was retrospective, clinical and
pathological data were reviewed locally rather than cen-
trally. We feel that our results were not deeply hampered
by this approach, as only standard clinical and patho-
logical variables were analysed; however, we cannot
exclude underreporting of pathological features. Our study
represents a real-world scenario in which a central review
is rarely performed, making the conclusions more gener-
ally applicable. Additionally, VENUSS and other defini-
tions were also evaluated in an independent cohort from
prospectively documented trial data, which may be con-
sidered the gold standard. Thirdly, it was not possible to
adjust for multiple non-measured confounders, such as
patient preference for follow-up imaging, imaging modal-
ities, co-morbidity, symptoms, laboratory values and per-
formance status, which were not available. However, the
aim of this study was to provide a simple score based on
routine pathological parameters. Papillary type 1 and 2
was only available in a subgroup of patients. It has been
suggested that nuclear grade may be used as a surrogate
for type [11], but there is no high-level evidence at present
to support this approach. Additionally, some centres do
no routinely grade PRCC. A proportion of type 2 PRCC
may be hereditary leiomyomatosis and renal cell cancer
(HLRCC), which may be another confounder given the
highly aggressive nature of this disease. For this study, we
only collected patients with documented sporadic PRCC,
but cannot exclude that some patients may have had
undocumented or undiagnosed HLRCC. As other
groups [3, 4], the current study did not identify papil-
lary type as a significant prognostic factor on multivari-
able analysis, but this may be due to the lack of central
pathology review. This is also true for the presence of
tumour necrosis and sarcomatoid features. It may be
the case that the presence of both pathological features
is not prognostic, but that a certain percentage is re-
quired to show statistical significance. Finally, we did
not obtain data on treatment of recurrent disease,
which was beyond the scope of this study. Instead, we
focused on the time interval from surgery to detection
of recurrence. Our proportion of patients with oligome-
tastatic recurrent disease was comparable to other stud-
ies [19, 20], which supports the validity of our dataset.
The current study reinforces the concept that, with rou-
tine follow-up imaging, oligometastatic and thus poten-
tially curable disease is detected in a significant
proportion of patients across all risk groups. Despite
these limitations, our model may form the basis for fol-
low-up risk stratification and inclusion criteria for adju-
vant trials.
Conclusions
We developed and tested a prognostic model for pa-
tients with clinically non-metastatic PRCC, which is
based on routine pathological variables. This model
may be superior to current standard models. This
tool could be used for tailoring postoperative surveil-
lance and defining inclusion into prospective adjuvant
clinical trials.
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